109434-22-2

Usage

Uses

Used in Nuclear Medicine Imaging:
2-METHOXYISOBYL ISOCYANIDE is used as a ligand for Technetium (99mTc) sestamibi, which is a radiopharmaceutical agent employed in nuclear medicine imaging. This application takes advantage of the compound's ability to form stable complexes with the radioactive isotope, allowing for the visualization of various physiological processes and the detection of abnormalities within the body.

InChI:InChI=1/C6H11NO/c1-6(2,8-4)5-7-3/h5H2,1-2,4H3

Upstream product

• 112129-25-6 N-formyl-2-methoxyisobutylamine 
• 503-38-8 trichloromethyl chloroformate 
• 89282-70-2 2-methoxyisobutyl amine 
• 7732-18-5 water 

Downstream Products

• 103694-84-4 tetrakis(2-methoxyisobutylisocyano) copper(I) tetrafluoroborate 

Relevant academic research and scientific papers

Preparation and biodistribution of novel 99mTc(CO) 3-CNR complexes for myocardial imaging

We evaluated lipophilicity and biodistribution of a series of 99mTc(CO)3-ether isonitrile complexes to determine whether different lipophilicity and structure of isonitrile ligands would improve the imaging properties of the radiopharmaceutical for the heart. Novel 99mTc(CO)3-MIBI analogs were prepared and analyzed by radio-HPLC, and their lipophilicity was determined. These new complexes could be bi- or tri-substituted in specified pH conditions like 99mTc(CO) 3-MIBI. These new complexes exhibited low liver, lungs and blood uptake compared with [99mTc(CO)3(MIBI)3] + though their heart uptake was not so high. Among these complexes, [99mTc(CO)3(EPI)2(OH2)]+ showed higher target to non-target ratios at 5 and 30 min post-injection than that of [99mTc(CO)3(MIBI)3]+. Copyright

Towards Cardiolite-Inspired Carbon Monoxide Releasing Molecules - Reactivity of d4, d5 Rhenium and d6 Manganese Carbonyl Complexes with Isocyanide Ligands

Carbon monoxide releasing molecules (CORMs) are investigated widely in synthetic and medicinal chemistry owing to the potential therapeutic applications of the CO gas. Organometallic carbonyl complexes are best suited to play the role of CO carriers as they allow the exogenous release of CO under controlled conditions, and the toxicity of the gas can be overcome. With the long-term goal of developing CORMs with similar properties to those of the sesta-methoxyisobutylisonitrile (sesta-mibi) 99mTc complex (Cardiolite), we have studied the reactivity of isocyanide ligands towards 16- and 17-electron cis-[Re(CO)2Br4]-/2- species and the [Mn(CO)5Br] complex. Six different isocyanide ancillary ligands (CNR), including mibi, were selected for this study. Their reactions with cis-dicarbonyl ReIII and ReII complexes were accompanied by two- and one-electron reduction of the metal center and resulted in the formation of stable cis-mer-[Re(CO)2(CNR)3Br] species, whereas the same reactions with [Mn(CO)5Br] gave fac-[Mn(CO)3(CNR)2Br] compounds. All of the complexes were fully characterized, and single-crystal X-ray diffraction structure determinations were performed for selected species. In addition, unique monocarbonyl complexes were obtained from the reactions of cis-[Re(CO)2Br4]- (1) with tert-butyl isocyanide and cis-[Re(CO)2Br4]2- (2) with mibi. The species, a heptacoordinate ReIII and a hexacoordinate ReII complex, respectively, were also characterized structurally. The CO-releasing profiles, the cytotoxic effects against 3T3 fibroblast cells, and the antibacterial properties of the compounds were also investigated. To develop CO-releasing molecules with properties similar to those of the sesta-methoxyisobutylisonitrile (sesta-mibi) 99mTc complex (Cardiolite), we study the reactivity of isocyanide ligands towards 16-, 17- and 18-electron rhenium and manganese carbonyl complexes. A combined experimental and theoretical approach elucidates the reaction pathway to the species.

METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE

The present invention relates to new synthetic methods for preparing 2-methoxyisobutylisonitrile and metal isonitrile complexes, such as tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluroroborate, which are used in the preparation of technetium (99mTc) Sestamibi, and novel intermediate compounds useful in such methods.

Method for synthesis and 99m C labelling of 2-alkoxyisobutylisonitrile

A new method for synthesizing 2-alkoxyisobutylisonitrile is provided in which isobutylene is used as the starting material. The haloalkoxylation of isobutylene in alcohol medium gives 2-alkoxyisobutylhalide which is then converted to 2-alkoxyisobutylamine. In the basic condition, the reaction of 2-alkoxyisobutylamine with chloroform produces 2-alkoxyisobutylisonitrile. The synthesis process contains three steps by which a higher yield is achieved. 2-Alkoxyisobutylisonitrile is labelled with technetium-99m by exchange labelling of stable tetrakis(2-alkoxyisobutylisonitrile)copper(I) complex. Tetrakis(2-alkoxyisobutylisonitrile)copper(I) complex can be prepared by the exchange of acetonitrile molecules in tetrakis(acetonitrile)copper(I) complex with isonitrile ligands.

Ether isonitriles and radiolabeled complexes thereof

Ether-substituted isonitriles, Tc99m complexes thereof, and processes for myocardial tissue radioimaging using the Tc99m complexes.

Process for preparing 2-methoxyisobutylisonitrile

A new process for preparing 2-methoxyisobutylisonitrile is described. 2-methoxyisobutylisonitrile is used in the preparation of Tc-99m hexakis (2-methoxyisobutylisonitrile). This cationic complex is useful as a myocardial perfusion agent.